Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.

A third way for drug addiction policy in Canada
![PJ2 Stock Price and Chart GETTEX:PJ2 TradingView [Video]](https://canadanewsvideo.com/wp-content/uploads/2023/03/mp_141982_0_logopreviewpng.png)
PJ2 Stock Price and Chart GETTEX:PJ2 TradingView [Video]
Categories
New tools or new competitors? The future of competition law in Canada